Condition: Nasopharyngeal Carcinoma (NPC) · Sponsor: Shanghai Henlius Biotech
The study is to explore the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic Nasopharyngeal Carcinoma (NPC) who failed or are intolerant to second-line herapy.
This description comes directly from the study's public registry record.
Wenhua Yu · +86 17638575068 · Wenhua_Yu1@henlius.com
Always discuss trial participation with your own doctor first.
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Dongguan People's Hospital | Dongguan, Guangdong, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| The First Affiliated Hospital of Guangdong Pharmaceutical University | Guangzhou, Guangdong, China | Recruiting |
| Zhongshan City People's Hospital | Guangzhou, Guangdong, China | Recruiting |
| Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen | Shenzhen, Guangdong, China | Recruiting |
| Guangxi Medical University Cancer Hospital | Nanning, Guangxi, China | Recruiting |
| Guizhou Medical University Cancer Hospital | Guiyang, Guizhou, China | Recruiting |
| Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology | Wuhan, Hubei, China | Recruiting |
| Union Hospital Tongji Medical College Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| Xiangya Hospital of Central South University | Changsha, Hunan, China | Recruiting |
| First Affiliated Hospital of Gannan Medical University | Ganzhou, Jiangxi, China | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06839066